Xcout IntelSign inSubscribe

Korsana Biosciences

KRSABiotechWaltham, MA, United States

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics. Its product pipeline includes several sGC stimulators, small molecules that act synergistically with nitric oxide on sGC to boost production of cyclic guanosine monophosphate. The company was founded on September 6, 2018 and is headquartered in Cambridge, MA.

Subscribe to see Korsana Biosciences’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event

Korsana Biosciences at a glance

Korsana Biosciences is a biotech company headquartered in Waltham, United States. It is publicly listed (KRSA) with a market capitalisation of $1.4B. Xcout tracks 27 named people at Korsana Biosciences, including Regina Graul (Chief Executive Officer, President & Director).

As of 16 November 2026. Source: Xcout Intel.

Industry
Biotech
Headquarters
Waltham, MA, United States
Market cap
$1.4B
Employees
1
Ticker
KRSA

Korsana Biosciences leadership

  • Regina GraulChief Executive Officer, President & Director
  • Jonathan VioliinCEO
  • Jonathan ViolinPresident, CEO, Secretary & Director
  • Mark Joseph VignolaChief Financial Officer
  • Rhonda ChickoChief Financial Officer
  • Wei GanChief Technical Officer

21 more named people on record for Korsana Biosciences, with roles, board committees and tenure — see the full roster →

Korsana Biosciences funding rounds before its IPO

Every round on record:

DateRoundAmountInvestors
Series A$150M3 named

Financing after the IPO — public offerings and SEC Form D private placements — is not listed as a funding round.

Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →

Investors

Korsana Biosciences competitors

A few of Korsana Biosciences's closest competitors — see the full list of competitors and alternatives →

Cyclerion Therapeutics, Inc.CYCN · BiotechCambridge, MA, United States
86% matchPublic

Cyclerion Therapeutics, Inc. operates as a biopharmaceutical company in the clinical development phase, concentrating on the discovery, advancement, and commercialization of therapeutic agents for debilitating central nervous system (CNS) disorders. Their leading experimental compound, CY6463, is a soluble guanylate cyclase (sGC) stimulator designed to cross the blood-brain barrier. It is presently in Phase IIa clinical assessments for managing mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS), as well as Alzheimer's disease with vascular involvement. Concurrently, CY6463 is undergoing Phase 1 trials for treating schizophrenia in adult populations. The company's research portfolio also features other promising candidates: Praliciguat, an orally administered systemic sGC stimulator, is in Phase II studies targeting resistant hypertension and diabetic nephropathy. Olinciguat, another sGC stimulator designed for oral intake with a vascular focus, is progressing through Phase II trials for sickle cell disease. Moreover, CY3018 is under development to address a range of CNS ailments. Cyclerion holds a licensing agreement with Akebia Therapeutics, Inc., covering the entire lifecycle from development and manufacturing to medical affairs and commercialization for certain pharmaceutical compounds and related products. The company was founded in 2018 and has its principal place of business in Cambridge, Massachusetts.

Market cap$15.7M
Employees1
Cyclerion Therapeutics, Inc. competitors & alternatives →

Get Korsana Biosciences's news by email

Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.

Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →

Something wrong or missing about Korsana Biosciences? Suggest a correction · Work at Korsana Biosciences? Claim this profile

Is this your company? Add the Xcout Intel badge to your website

Free, for any company on Xcout Intel. It links visitors to this profile.

Korsana Biosciences on Xcout Intel

Share this card

Post the link and the card appears automatically — each network fetches the image itself.

Korsana Biosciences — share card preview

Instagram, TikTok and Slack canvases don't expand links — download the card as a PNG and post it as an image instead.

More on Korsana Biosciences in Xcout Intel

  • 27 named people with titles, LinkedIn and board committees
  • 1 funding round before the IPO with the investors in each, and who they co-invest with
  • 1 corporate event with sources — deals, leadership changes, layoffs
  • The full competitor set, tracking, exports and API access
Subscribe to Xcout Intel →